The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InIn a move reflecting resilience within the diagnostic services and energy sectors, Labcorp and TechnipFMC announced robust financial results for the second quarter of 2026. Labcorp reported revenue of $3.73 billion, marking a 5.8% increase year-over-year, which prompted management to raise its full-year 2026 guidance. Meanwhile, TechnipFMC recorded revenue of $2.76 billion, a 9% annual increase, with net income reaching $362.7 million.
These positive results come at a time when financial data shows stability in profitability levels, with reports highlighting margin expansion and business momentum for Labcorp. Per market data, these figures reflect the companies' ability to manage costs effectively despite global economic challenges. Labcorp's decision to raise its annual outlook suggests management confidence in sustained demand for diagnostic and biopharma laboratory services through the second half of the year.
Regarding price levels, LH stock stood at $314.23 while FTI stock closed at $72.39 (at close July 28, 2026). Investors should monitor support levels for LH at $304.73 and FTI at $72.10, representing the session lows from July 28. With no major upcoming catalysts in the economic calendar directly impacting these firms, focus will remain on profit margin sustainability and the impact of foreign currency translation on international revenues.